Deyin Guo

Jan 21, 2025 | nature.com | Yongzhi Lu |Qi Yang |Ting Ran |Wei Zhang |Deyin Guo |Xinwen Chen | +1 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-54462-0, published online 23 November 2024In this article there is an error in Figure 1 where the residue labelling incorrectly read E164 and should be D164. The original article has been corrected.

Nov 22, 2024 | nature.com | Yongzhi Lu |Qi Yang |Ting Ran |Wei Zhang |Deyin Guo |Xinwen Chen | +1 more

AbstractThe RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CLpro), and papain-like protease (PLpro) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CLpro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CLpro from SARS-CoV-2, which makes it necessary to develop antivirals with novel mechanisms.

Dec 13, 2023 | nature.com | Zhen Wang |Deyin Guo

Dear Editor, The novel coronavirus SARS-CoV-2 rapidly evolutes to increase its infectivity and transmissibility, facilitates its immune escape, impairs vaccine efficacy, and currently causes repeated infections in human, which is mainly determined by the accumulated mutations in spike (S).1 Transmembrane S is a heavily glycosylated protein on the surface of the virion as homotrimer, responsible for binding to human angiotensin-converting enzyme 2 (hACE2) receptor.2 While the architecture of S...

Apr 26, 2023 | nature.com | Deyin Guo

Dear Editor,The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has resulted in its continuous evolution and the emergence of numerous subvariants of Omicron (https://gisaid.org/).